Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that the Company will present and conduct 1-on-1 meetings with investors at the 2022 Wells Fargo Healthcare Conference and H.C. Wainwright 24th Annual Global Investment Conference.

2022 Wells Fargo Healthcare Conference Date: Friday, September 9, 2022 Time: 8:00 a.m. ET Speaker: Adelene Perkins, Chief Executive Officer Format: In-person fireside chat and 1-on-1 meetings Webcast Registration Link

H.C. Wainwright 24th Annual Global Investment Conference Date: Monday, September 12, 2022 Time: Presentation available at 7:00 a.m. ET Speaker: Adelene Perkins, Chief Executive Officer Format: Virtual company presentation and 1-on-1 meetings Webcast Registration Link

A replay of the presentations will be available in the Investors/Media section of Infinity's website at www.infi.com for 90 days following the events.

About Infinity and Eganelisib Infinity Pharmaceuticals, Inc. (“Infinity” or the “Company”), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which is designed to address a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Opdivo® is a registered trademark of Bristol Myers Squibb. Tecentriq® is a registered trademark of Genentech, Inc. Abraxane® is a registered trademark of Abraxis BioScience, LLC., a wholly owned subsidiary of Bristol Myers Squibb Company. Avastin® is a registered trademark of Genentech, Inc.

Investor Relations: Kevin Lui Real Chemistry klui@realchemistry.com

Infinity Pharmaceuticals (NASDAQ:INFI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Infinity Pharmaceuticals.
Infinity Pharmaceuticals (NASDAQ:INFI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Infinity Pharmaceuticals.